Cargando…

Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: the NeuroToolKit

BACKGROUND: Alzheimer’s disease (AD) is a complex and heterogeneous disease, which requires reliable biomarkers for diagnosis and monitoring disease activity. Preanalytical protocol and technical variability associated with biomarker immunoassays makes comparability of biomarker data across multiple...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johnson, Sterling C., Suárez-Calvet, Marc, Suridjan, Ivonne, Minguillón, Carolina, Gispert, Juan Domingo, Jonaitis, Erin, Michna, Agata, Carboni, Margherita, Bittner, Tobias, Rabe, Christina, Kollmorgen, Gwendlyn, Zetterberg, Henrik, Blennow, Kaj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883877/ https://www.ncbi.nlm.nih.gov/pubmed/36709293 http://dx.doi.org/10.1186/s13195-023-01168-y

Ejemplares similares

Age, sex and APOE-ε4 modify the balance between soluble and fibrillar β-amyloid in non-demented individuals: topographical patterns across two independent cohorts
por: Cacciaglia, Raffaele, et al.
Publicado: (2022)

Brain alterations in the early Alzheimer’s continuum with amyloid-β, tau, glial and neurodegeneration CSF markers
por: Salvadó, Gemma, et al.
Publicado: (2022)

Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer’s continuum
por: Salvadó, Gemma, et al.
Publicado: (2022)

Enhancing the Sensitivity of Memory Tests: Reference Data for the Free and Cued Selective Reminding Test and the Logical Memory Task from Cognitively Healthy Subjects with Normal Alzheimer’s Disease Cerebrospinal Fluid Biomarker Levels
por: Brugulat-Serrat, Anna, et al.
Publicado: (2021)

Associations between diffusion MRI microstructure and cerebrospinal fluid markers of Alzheimer's disease pathology and neurodegeneration along the Alzheimer's disease continuum
por: Moody, Jason F., et al.
Publicado: (2022)

Cerebral amyloid‐β load is associated with neurodegeneration and gliosis: Mediation by p‐tau and interactions with risk factors early in the Alzheimer's continuum
por: Salvadó, Gemma, et al.
Publicado: (2021)

Asthma amplifies dementia risk: Evidence from CSF biomarkers and cognitive decline
por: Nair, Ajay Kumar, et al.
Publicado: (2022)

Prepandemic Alzheimer Disease Biomarkers and Anxious-Depressive Symptoms During the COVID-19 Confinement in Cognitively Unimpaired Adults
por: Akinci, Muge, et al.
Publicado: (2022)

Genetically predicted telomere length and Alzheimer’s disease endophenotypes: a Mendelian randomization study
por: Rodríguez-Fernández, Blanca, et al.
Publicado: (2022)

Crosswalk study on blood collection‐tube types for Alzheimer's disease biomarkers
por: Jonaitis, Erin M., et al.
Publicado: (2022)

Impact of asthma on the brain: evidence from diffusion MRI, CSF biomarkers and cognitive decline
por: Nair, Ajay Kumar, et al.
Publicado: (2023)

CSF metabolites associated with biomarkers of Alzheimer’s disease pathology
por: Dong, Ruocheng, et al.
Publicado: (2023)

Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer’s continuum
por: Vilor-Tejedor, Natalia, et al.
Publicado: (2021)

Insulin resistance is related to cognitive decline but not change in CSF biomarkers of Alzheimer's disease in non‐demented adults
por: Ennis, Gilda E., et al.
Publicado: (2021)

Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease
por: Erickson, Pontus, et al.
Publicado: (2023)

Biological brain age prediction using machine learning on structural neuroimaging data: Multi-cohort validation against biomarkers of Alzheimer’s disease and neurodegeneration stratified by sex
por: Cumplido-Mayoral, Irene, et al.
Publicado: (2023)

Effect of Pathway-specific Polygenic Risk Scores for Alzheimer’s Disease (AD) on Rate of Change in Cognitive Function and AD-related Biomarkers among Asymptomatic Individuals
por: Xu, Yuexuan, et al.
Publicado: (2023)

CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET: A Cross-sectional Study
por: Milà-Alomà, Marta, et al.
Publicado: (2021)

An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum
por: Van Hulle, Carol, et al.
Publicado: (2020)

Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum
por: Benedet, Andréa L., et al.
Publicado: (2021)

Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum
por: Milà‐Alomà, Marta, et al.
Publicado: (2020)

Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer’s disease
por: Grau-Rivera, Oriol, et al.
Publicado: (2021)

Neuroimaging of tissue microstructure as a marker of neurodegeneration in the AT(N) framework: defining abnormal neurodegeneration and improving prediction of clinical status
por: Gallagher, Rigina L., et al.
Publicado: (2023)

Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profile
por: Milà-Alomà, Marta, et al.
Publicado: (2021)

Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected
por: Suárez‐Calvet, Marc, et al.
Publicado: (2020)

Editorial: Blood Biomarkers of Neurodegenerative Diseases
por: Karikari, Thomas K., et al.
Publicado: (2022)

Plasma biomarkers for neurodegenerative disorders: ready for prime time?
por: Balogun, Wasiu G., et al.
Publicado: (2023)

Gut inflammation associated with age and Alzheimer’s disease pathology: a human cohort study
por: Heston, Margo B., et al.
Publicado: (2023)

Reference Data for Attentional, Executive, Linguistic, and Visual Processing Tests Obtained from Cognitively Healthy Individuals with Normal Alzheimer’s Disease Cerebrospinal Fluid Biomarker Levels
por: López-Martos, David, et al.
Publicado: (2023)

Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers
por: Salvadó, Gemma, et al.
Publicado: (2019)

Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders
por: Yilmaz, Aylin, et al.
Publicado: (2019)

Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers
por: Camporesi, Elena, et al.
Publicado: (2021)

Elevated CSF angiopoietin-2 correlates with blood-brain barrier leakiness and markers of neuronal injury in early Alzheimer’s disease
por: Miners, James, et al.
Publicado: (2023)

Current Diagnostic Pathways for Alzheimer’s Disease: A Cross-Sectional Real-World Study Across Six Countries
por: Roth, Sophie, et al.
Publicado: (2023)

Reply to “Pathway for ascertaining the role of uric acid in neurodegenerative diseases,” Roman Youssef
por: Dehlin, Mats, et al.
Publicado: (2022)

Cerebrospinal fluid microglia and neurodegenerative markers in twins concordant and discordant for psychotic disorders
por: Johansson, Viktoria, et al.
Publicado: (2016)

Effects of pre‐analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2020)

The Rationale Behind the New Alzheimer’s Disease Conceptualization: Lessons Learned During the Last Decades
por: Molinuevo, José Luis, et al.
Publicado: (2018)

Differential effects of neurodegeneration biomarkers on subclinical cognitive decline
por: Merluzzi, Andrew P., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_potcngd791cl8k648fm56c3bkp